Celestra Inc, formerly Clinomics Inc, is a Korea-based company principally operates precision medical business based on genome-based healthcare and liquid biopsy platforms. The Company provides genome-based healthcare products and services that predict physical characteristics and diseases based on genome diagnosis and examination. The Company is engaged in the sale of medical devices and cancer diagnosis and monitoring that extract blood cells and deoxyribo nucleic acid (DNA) to diagnose patients. The Company is developing multi-omics-based early diagnosis service technology for diseases such as cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 03/04/2025			5-day change	1st Jan Change
5,250.00 ^KRW	-20.63%		-.--%	-

07/04/25	Celestra Inc. Auditor Raises 'Going Concern' Doubt	CI
18/03/25	Clinomics Inc. announced that it has received KRW 5.5 billion in funding	CI

Market Cap	13.41B 9.46M 8.19M 7.65M 6.99M 13.18M 902M 13.38M 89.72M 35.2M 451M 35.5M 34.73M 1.5B	P/E 2024	-0.4x	P/E 2025	-1.14x
Enterprise Value	17.19B 12.12M 10.5M 9.81M 8.97M 16.9M 1.16B 17.16M 115M 45.14M 579M 45.53M 44.53M 1.93B	EV / Sales 2024	5.8x	EV / Sales 2025	8.56x
Free-Float	78.31%	Yield 2024 *	-	Yield 2025	-

07/04/25	Celestra Inc. Auditor Raises 'Going Concern' Doubt	CI
18/03/25	Clinomics Inc. announced that it has received KRW 5.5 billion in funding	CI
13/03/25	Mirae Asset Securities Co., Ltd. agreed to acquire New Oriental Hotel Co., Ltd from Clinomics Inc. for KRW 14.5 billion.	CI
07/08/24	Clinomics Inc. announced that it expects to receive KRW 10 billion in funding	CI
17/05/24	Clinomics Inc. announced that it has received KRW 4 billion in funding	CI
14/05/24	Clinomics Inc. announced that it expects to receive KRW 4 billion in funding	CI
08/05/24	Clinomics Inc. announced that it has received KRW 32.600017466 billion in funding from Cdbio Co., Ltd., Daon Engineering Co., Ltd, Baro Savings Bank, The Korea Securities Finance Corporation	CI
03/05/24	Clinomics Inc. agreed to acquire New Oriental Hotel Co., Ltd from Daon Engineering Co., Ltd and Gi-dong Song for KRW 18.5 billion.	CI
21/03/24	Clinomics Inc. Auditor Raises 'Going Concern' Doubt	CI
15/12/23	Clinomics Inc. announced that it expects to receive KRW 15 billion in funding from Busan Equity Partners Co., Ltd.	CI
30/08/23	Tranche Update on Clinomics Inc.'s Equity Buyback Plan announced on August 30, 2023.	CI
30/08/23	Clinomics Inc. announces an Equity Buyback for 124,764 shares.	CI
30/08/23	Clinomics Inc.'s Equity Buyback announced on August 30, 2023, has closed with 124,764 shares, representing 0.61% for KRW 299.43 million.	CI

3 years	4,245	54,900
5 years	4,245	143,000
10 years	4,245	261,500

Celestra Inc. Stock

Stocks

A352770

KR7352770002

Biotechnology & Medical Research

Valuation: Celestra Inc.

Latest news : Celestra Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Celestra Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

Manager	Title	Age	Since
Seo-Hyeon Baek CEO	Chief Executive Officer	30	29/03/2024
Jong-Bin Baek AUD	Comptroller/Controller/Auditor	47	31/03/2025

Director	Title	Age	Since
Seo-Hyeon Baek BRD	Director/Board Member	30	29/03/2024
Hoo-Hyuk Hong BRD	Director/Board Member	42	25/09/2025
Young-Il Yoo BRD	Director/Board Member	41	14/06/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELESTRA INC.	-20.63%	-.--%	-.--%	-89.46%	9.46M
LONZA GROUP AG	-0.79%	+3.13%	+6.02%	+15.94%	50.03B
REVOLUTION MEDICINES, INC.	+0.89%	+13.44%	+491.34%	+594.30%	44.36B
BEONE MEDICINES AG	+3.08%	+14.42%	+24.57%	+81.39%	40.82B
IQVIA HOLDINGS INC.	+1.38%	+3.70%	+34.54%	+9.11%	39.83B
CELLTRION, INC.	+0.85%	+10.32%	+21.22%	+47.64%	32.51B
ASCENDIS PHARMA A/S	+0.08%	+5.00%	-	-	16.85B
MEDPACE HOLDINGS, INC.	+1.99%	+5.08%	+38.70%	+125.08%	16.81B
EUROFINS SCIENTIFIC SE	-0.29%	+1.45%	+5.37%	+21.22%	14.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+3.56%	+19.98%	+86.23%	+27.29%	13.22B
Average	-0.99%	+248.34%	+78.67%	+92.50%	26.85B
Weighted average by Cap.	+1.06%	+295.01%	+107.43%	+139.71%

	2024	2025
Net sales	8.5B 6M 5.19M 4.85M 4.43M 8.36M 572M 8.49M 56.9M 22.33M 286M 22.51M 22.02M 953M	2.01B 1.42M 1.23M 1.15M 1.05M 1.97M 135M 2M 13.44M 5.27M 67.56M 5.32M 5.2M 225M
Net income	-46.92B -33.09M -28.65M -26.78M -24.47M -46.12M -3.16B -46.84M -314M -123M -1.58B -124M -122M -5.26B	-11.77B -8.3M -7.19M -6.72M -6.14M -11.57M -792M -11.75M -78.77M -30.91M -396M -31.17M -30.49M -1.32B
Net Debt	29.34B 20.69M 17.91M 16.74M 15.3M 28.84M 1.97B 29.29M 196M 77.04M 987M 77.69M 76M 3.29B	3.79B 2.67M 2.31M 2.16M 1.97M 3.72M 255M 3.78M 25.33M 9.94M 127M 10.02M 9.8M 424M